Fortrea announces strategic collaboration with Emery Pharma

Fortrea (FTRE) announced a strategic collaboration with Emery Pharma, an analytical and bioanalytical contract research organization, CRO, providing testing services under current Good Manufacturing Practice, cGMP, and Good Laboratory Practice, GLP, to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine, MNP, testing of rifampin, the preferred drug for drug-drug interaction, DDI, studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration, FDA, guidelines. Fortrea has selected Emery Pharma due to its strong capabilities in analytical and bioanalytical testing in support of Fortrea’s global clinical programs. Emery Pharma’s expertise in this area supports Fortrea’s ability to offer rifampin as an agent for inducing the CYP3A4 isoenzyme in DDI studies. The collaboration announced today allows sponsors to conduct DDI assessments using rifampin, which is frequently named as the preferred agent in these studies, due to its safety and tolerability profile.